A neurocognitive model for understanding treatment action in depression

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 370, Issue 1677, 2015, Pages

  Warren, Matthew B ^a   Pringle, Abbie ^a   Harmer, Catherine J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

Depression; Emotional processing; Neuroimaging

Indexed keywords

COGNITION; DISEASE TREATMENT; DRUG; HEALTH CARE; HUMAN ACTIVITY; NERVOUS SYSTEM DISORDER; NEUROLOGY; PSYCHOLOGY;

ANTIDEPRESSANT AGENT;

BIOLOGICAL MODEL; COGNITION; DEPRESSION; DRUG DEVELOPMENT; DRUG EFFECTS; EMOTION; HUMAN; PATHOPHYSIOLOGY; PSYCHOLOGICAL MODEL; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; COGNITION; DEPRESSION; DRUG DISCOVERY; EMOTIONS; HUMANS; MODELS, NEUROLOGICAL; MODELS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84938497845     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2014.0213     Document Type: Article

References (109)

1. Hariri AR, Mattay VS, Tessitore A, Fera F, Smith WG, Weinberger DR. 2002 Dextroamphetamine modulates the response of the human amygdala. Neuropsychopharmacology 27, 1036–1040. (doi:10.1016/s0893-133x(02)00373-1)
2. Del-Ben CM, Ferreira CA, Sanchez TA, Alves-Neto WC, Guapo VG, de Araujo DB, Graeff FG. 2012 Effects of diazepam on BOLD activation during the processing of aversive faces J. Psychopharmacol. 26, 443–451. (doi:10.1177/0269881110389092)
3. Frazer A, Benmansour S. 2002 Delayed pharmacological effects of antidepressants. Mol Psychiatry 7(1), S23–S28. (doi:10.1038/sjmp.4001015)
4. Stahl SM. 1998 Mechanism of action of serotonin selective reuptake inhibitors. J. Affect. Disord. 51, 215–235. (doi:10.1016/S0165-0327(98)00221-3)
5. Perera TD et al. 2011 Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates PLoS ONE 6, e17600. (doi:10.1371/journal.pone0017600)
6. Becker S, Wojtowicz JM. 2007 A model of hippocampal neurogenesis in memory and mood disorders. Trends Cogn. Sci. 11, 70–76. (doi:10.1016/j.tics.2006.10.013)
7. Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM. 2003 Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 28, 148–152. (doi:10.1038/sj.npp.1300004)
8. Harmer CJ, Hill SA, Taylor MJ, Cowen PJ, Goodwin GM. 2003 Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am. J. Psychiatry 160, 990–992. (doi:10.1176/appi.ajp.160.5.990)
9. Harmer CJ, O’Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, Goodwin GM, Cowen PJ. 2009 Effect of acute antidepressant administration on negative affective bias in depressed patients Am. J. Psychiatry 166, 1178–1184. (doi:10.1176/appi.ajp.2009.09020149)
10. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z 2006 Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch. Gen. Psychiatry 63, 1217–1223. (doi:10.1001/archpsyc.63.11.1217)
11. Roiser JP, Elliott R, Sahakian BJ. 2012 Cognitive mechanisms of treatment in depression Neuropsychopharmacology 37, 117–136. (doi:10.1038/npp.2011.183)
12. Bradley BP, Mogg K, Williams R. 1995 Implicit and explicit memory for emotion-congruent information in clinical depression and anxiety. Behav. Res. Ther 33, 755–770. (doi:10.1016/0005-7967(95)00029-W)
13. Bourke C, Douglas K, Porter R. 2010 Processing of facial emotion expression in major depression: a review. Aust. N. Z. J. Psychiatry 44, 681–696 (doi:10.3109/00048674.2010.496359)
14. Hamilton JP, Etkin A, Furman DJ, Lemus MG, Johnson RF, Gotlib IH. 2012 Functional neuroimaging of major depressive disorder: a metaanalysis and new integration of baseline activation and neural response data. Am. J. Psychiatry 169, 693–703. (doi:10.1176/appi.ajp.2012.11071105)
15. Disner SG, Beevers CG, Haigh EAP, Beck AT. 2011 Neural mechanisms of the cognitive model of depression. Nat. Rev. Neurosci. 12, 467–477 (doi:10.1038/nrn3027)
16. Gonul AS, Kula M, Bilgin AG, Tutus A, Oguz A. 2004 The regional cerebral blood flow changes in major depressive disorder with and without psychotic features. Prog. Neuropsychopharmacol. Biol Psychiatry 28, 1015–1021. (doi:10.1016/j.pnpbp2004.05.036)
17. Suslow T et al. 2010 Automatic mood-congruent amygdala responses to masked facial expressions in major depression. Biol. Psychiatry 67, 155–160 (doi:10.1016/j.biopsych.2009.07.023)
18. Teasdale JD. 1988 Cognitive vulnerability to persistent depression. Cogn. Emotion 2, 247–274 (doi:10.1080/02699938808410927)
19. Bouhuys AL, Geerts E, Gordijn MC. 1999 Depressed patients’ perceptions of facial emotions in depressed and remitted states are associated with relapse: a longitudinal study. J. Nerv. Ment. Dis. 187, 595–602 (doi:10.1097/00005053-199910000-00002)
20. Browning M, Holmes EA, Charles M, Cowen PJ, Harmer CJ. 2012 Using attentional bias modification as a cognitive vaccine against depression. Biol Psychiatry 72, 572–579. (doi:10.1016/j.biopsych2012.04.014)
21. MacLeod C, Rutherford E, Campbell L, Ebsworthy G, Holker L. 2002 Selective attention and emotional vulnerability: assessing the causal basis of their association through the experimental manipulation of attentional bias. J. Abnorm. Psychol. 111, 107–123. (doi:10.1037/0021-843X.111.1.107)
22. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM 2004 Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am. J. Psychiatry 161, 1256–1263. (doi:10.1176/appi.ajp.161.7.1256)
23. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. 2006 Antidepressant drug treatment modifies the neural processing of nonconscious threat cues Biol. Psychiatry 59, 816–820. (doi:10.1016/jbiopsych.2005.10.015)
24. Murphy SE, Yiend J, Lester KJ, Cowen PJ, Harmer CJ 2009 Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers Int. J. Neuropsychopharmacol. 12, 169–179 (doi:10.1017/s1461145708009164)
25. Murphy SE, Longhitano C, Ayres RE, Cowen PJ, Harmer CJ. 2006 Tryptophan supplementation induces a positive bias in the processing of emotional material in healthy female volunteers Psychopharmacology 187, 121–130. (doi:10.1007/s00213-006-0401-8)
26. Harmer CJ, de Bodinat C, Dawson GR, Dourish CT, Waldenmaier L, Adams S, Cowen PJ, Goodwin GM 2011 Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J. Psychopharmacol. 25, 1159–1167 (doi:10.1177/0269881110376689)
27. Shiroma PR, Thuras P, Johns B, Lim KO. 2014 Emotion recognition processing as early predictor of response to 8-week citalopram treatment in latelife depression. Int. J. Geriatr. Psychiatry. 29, 1132–1139. (doi:10.1002/gps.4104)
28. Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson IM. 2009 The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. J. Affect. Disord 118, 87–93. (doi:10.1016/j.jad.2009.01.028)
29. Di Simplicio M, Doallo S, Costoloni G, Rohenkohl G, Nobre AC, Harmer CJ. 2014 ‘Can you look me in the face?’ Short-term SSRI administration reverts avoidant ocular face exploration in subjects at risk for psychopathology. Neuropsychopharmacology 39, 3059–3066. (doi:10.1038/npp.2014.159)
30. Murphy SE, Norbury R, O’Sullivan U, Cowen PJ, Harmer CJ. 2009 Effect of a single dose of citalopram on amygdala response to emotional faces. Br. J. Psychiatry 194, 535–540. (doi:10.1192/bjp.bp.108.056093)
31. Browning M, Reid C, Cowen PJ, Goodwin GM, Harmer CJ. 2007 A single dose of citalopram increases fear recognition in healthy subjects J. Psychopharmacol. 21, 684–690. (doi:10.1177/0269881106074062)
32. Miskowiak K, Papadatou-Pastou M, Cowen PJ, Goodwin GM, Norbury R, Harmer CJ. 2007 Single dose antidepressant administration modulates the neural processing of self-referent personality trait words. NeuroImage 37, 904–911. (doi:10.1016/jneuroimage.2007.05.036)
33. Harmer CJ, Heinzen J, O’Sullivan U, Ayres RA, Cowen PJ. 2008 Dissociable effects of acute antidepressant drug administration on subjective and emotional processing measures in healthy volunteers Psychopharmacology 199, 495–502. (doi:10.1007/s00213-007-1058-7)
34. Arnone D, Horder J, Cowen PJ, Harmer CJ. 2009 Early effects of mirtazapine on emotional processing. Psychopharmacology 203, 685–691 (doi:10.1007/s00213-008-1410-6)
35. Norbury R, Taylor MJ, Selvaraj S, Murphy SE, Harmer CJ, Cowen PJ. 2009 Short-term antidepressant treatment modulates amygdala response to happy faces. Psychopharmacology 206, 197–204. (doi:10.1007/s00213-009-1597-1)
36. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ. 2007 Short-term antidepressant treatment and facial processing. Functional magnetic resonance imaging study. Br. J. Psychiatry 190, 531–532. (doi:10.1192/bjp.bp.106.031393)
37. Godlewska BR, Norbury R, Selvaraj S, Cowen PJ, Harmer CJ. 2012 Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol. Med. 42, 2609–2617. (doi:10.1017/s0033291712000591)
38. Di Simplicio M, Norbury R, Reinecke A, Harmer CJ 2014 Paradoxical effects of short-term antidepressant treatment in fMRI emotional processing models in volunteers with high neuroticism. Psychol. Med. 44, 241–252. (doi:10.1017/S0033291713000731)
39. Anderson IM, Juhasz G, Thomas E, Downey D, McKie S, Deakin JF, Elliott R. 2011 The effect of acute citalopram on face emotion processing in remitted depression: a pharmacoMRI study. Eur Neuropsychopharmacol. 21, 140–148. (doi:10.1016/j.euroneuro.2010.06.008)
40. Grady CL, Siebner HR, Hornboll B, Macoveanu J, Paulson OB, Knudsen GM. 2013 Acutepharmacologically induced shifts in serotonin availability abolish emotion-selective responses to negative face emotions in distinct brain networks Eur. Neuropsychopharmacol. 23, 368–378. (doi:10.1016/j.euroneuro.2012.06.003)
41. Anderson IM, Del-Ben CM, McKie S, Richardson P, Williams SR, Elliott R, Deakin JF. 2007 Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. Neuroreport 18, 1351–1355. (doi:10.1097/WNR.0b013e3282742115)
42. Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, Elliott R, Dolan M, Anderson IM. 2005 The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an fMRI study. Neuropsychopharmacology 30, 1724–1734. (doi:10.1038/sj.npp.1300728)
43. Bigos KL, Pollock BG, Aizenstein HJ, Fisher PM, Bies RR, Hariri AR. 2008 Acute 5-HT reuptake blockade potentiates human amygdala reactivity Neuropsychopharmacology 33, 3221–3225. (doi:10.1038/npp.2008.52)
44. Rawlings NB, Norbury R, Cowen PJ, Harmer CJ. 2010 A single dose of mirtazapine modulates neural responses to emotional faces in healthy people Psychopharmacology 212, 625–634. (doi:10.1007/s00213-010-1983-8)
45. Harmer CJ. 2012 Emotional processing and antidepressant action. Curr. Top. Behav. Neurosci 14, 209–222. (doi:10.1007/78542012210)
46. Ma Y. 2014 Neuropsychological mechanism underlying antidepressant effect: a systematic metaanalysis Mol. Psychiatry. 20, 311–319. (doi:10.1038/mp.2014.24)
47. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ. 2008 The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study. Mol. Psychiatry 13, 1011–1020. (doi:10.1038/sj.mp.4002091)
48. Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B. 2010 Reboxetine for acute treatment of major depression: systematic review and metaanalysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341. (doi:10.1136/bmj.c4737)
49. Wiles NJ, Fischer K, Cowen P, Nutt D, Peters TJ, Lewis G, White IR. 2014 Allowing for nonadherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial Psychol. Med. 44, 2855–2866. (doi:10.1017/S0033291714000221)
50. Craske MG, Wolitzky-Taylor KB, Mineka S, Zinbarg R, Waters AM, Vrshek-Schallhorn S, Epstein A, Naliboff B, Ornitz E. 2012 Elevated responding to safe conditions as a specific risk factor for anxiety versus depressive disorders: evidence from a longitudinal investigation. J. Abnorm. Psychol. 121, 315–324 (doi:10.1037/a0025738)
51. Mogg K, Bradley B. 2005 Attentional bias in generalized anxiety disorder versus depressive disorder. Cogn. Ther. Res. 29, 29–45. (doi:10.1007/s10608-005-1646-y)
52. Griebel G, Moreau JL, Jenck F, Misslin R, Martin JR 1994 Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 113, 463–470.doi:10.1007/BF02245224
53. Pringle A, McCabe C, Cowen PJ, Harmer CJ. 2013 Antidepressant treatment and emotional processing: can we dissociate the roles of serotonin and noradrenaline? J. Psychopharmacol. 27, 719–731 (doi:10.1177/0269881112474523)
54. Golinkoff M, Sweeney JA. 1989 Cognitive impairments in depression. J. Affect. Disord. 17, 105–112. (doi:10.1016/0165-0327(89)90032-3)
55. Castaneda AE, Tuulio-Henriksson A, Marttunen M, Suvisaari J, Lonnqvist J. 2008 A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. J. Affect. Disord. 106, 1–27. (doi:10.1016/j.jad.2007.06.006)
56. Fu CH et al. 2004 Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, eventrelated functional magnetic resonance imaging study. Arch. Gen. Psychiatry 61, 877–889. (doi:10.1001/archpsyc.61.9.877)
57. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. 2001 Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol. Psychiatry 50, 651–658. (doi:10.1016/S0006-3223(01)01263-X)
58. Fu CH et al. 2007 Neural responses to happy facial expressions in major depression following antidepressant treatment. Am. J. Psychiatry 164, 599–607. (doi:10.1176/appi.ajp.164.4.599)
59. Hirschfeld RM, Klerman GL, Lavori P, Keller MB, Griffith P, Coryell W. 1989 Premorbid personality assessments of first onset of major depression Arch. Gen. Psychiatry 46, 345–350. (doi:10.1001/archpsyc.1989.01810040051008)
60. Saklofske DH, Kelly IW, Janzen BL. 1995 Neuroticism, depression, and depression proneness Person. Individual Diff. 18, 27–31. (doi:10.1016/0191-8869(94)00128-F)
61. Chan SW, Goodwin GM, Harmer CJ. 2007 Highly neurotic never-depressed students have negative biases in information processing. Psychol. Med. 37, 1281–1291. (doi:10.1017/S0033291707000669)
62. Chan SW, Harmer CJ, Goodwin GM, Norbury R. 2008 Risk for depression is associated with neural biases in emotional categorisation. Neuropsychologia 46, 2896–2903. (doi:10.1016/j.neuropsychologia.200805.030)
63. Jonassen R, Chelnokova O, Harmer C, Leknes S, Landro NI. 2014 A single dose of antidepressant alters eye-gaze patterns across face stimuli in healthy women. Psychopharmacology. 232, 953–958. (doi:10.1007/s00213-014-3729-5)
64. Di Simplicio M, Norbury R, Harmer CJ. 2012 Short-term antidepressant administration reduces negative self-referential processing in the medial prefrontal cortex in subjects at risk for depression Mol. Psychiatry 17, 503–510. (doi:10.1038/mp2011.16)
65. Shaw K, Turner J, Del Mar C. 2002 Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst. Rev. 1, Cd003198. (doi:10.1002/14651858.cd003198)
66. Quera Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, Lofaso F, Guilleminault C 2007 Major depressive disorder, sleep EEG and agomelatine: an open-label study Int. J. Neuropsychopharmacol. 10, 691–696 (doi:10.1017/s1461145707007754)
67. Terman M, Terman JS. 2006 Controlled trial of naturalistic dawn simulation and negative air ionization for seasonal affective disorder Am. J. Psychiatry 163, 2126–2133. (doi:10.1176/appi.ajp.163.12.2126)
68. Harmer CJ, Charles M, McTavish S, Favaron E, Cowen PJ. 2012 Negative ion treatment increases positive emotional processing in seasonal affective disorder Psychol. Med. 42, 1605–1612. (doi:10.1017/S0033291711002820)
69. Shiozawa P, Fregni F, Bensenor IM, Lotufo PA, Berlim MT, Daskalakis JZ, Cordeiro Q, Brunoni AR 2014 Transcranial direct current stimulation for major depression: an updated systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 17, 1443–1452. (doi:10.1017/s1461145714000418)
70. Nitsche MA, Koschack J, Pohlers H, Hullemann S, Paulus W, Happe S. 2012 Effects of frontal transcranial direct current stimulation on emotional state and processing in healthy humans. Front Psychiatry 3, 58. (doi:10.3389/fpsyt.2012.00058)
71. Ironside M, ƠShea J, Cowen PJ, Harmer CJ. In press Frontal cortex stimulation reduces vigilance to threat: implications for the treatment of depression and anxiety. Biol. Psych. (doi:10.1016/j.biopsych2015.06.012)
72. Brunoni AR, Zanao TA, Vanderhasselt MA, Valiengo L, de Oliveira JF, Boggio PS, Lotufo PA, Bensenor IM, Fregni F. 2014 Enhancement of affective processing induced by bifrontal transcranial direct current stimulation in patients with major depression. Neuromodulation 17, 138–142. (doi:10.1111/ner.12080)
73. Hilimire MR, Mayberg HS, Holtzheimer PE, Broadway JM, Parks NA, DeVylder JE, Corballis PM 2015 Effects of subcallosal cingulate deep brain stimulation on negative self-bias in patients with treatment-resistant depression. Brain Stimul. 8, 185–191. (doi:10.1016/j.brs.2014.11.010)
74. Lamers F et al. 2011 Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J. Clin. Psychiatry 72, 341–348 (doi:10.4088/JCP.10m06176blu)
75. Mogg K, Bradley BP. 2002 Selective orienting of attention to masked threat faces in social anxiety Behav. Res. Ther. 40, 1403–1414. (doi:10.1016/S0005-7967(02)00017-7)
76. Mogg K, Baldwin DS, Brodrick P, Bradley BP 2004 Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder Psychopharmacology 176, 466–470. (doi:10.1007/s00213-004-1902-y)
77. Blair RJ, Curran HV. 1999 Selective impairment in the recognition of anger induced by diazepam Psychopharmacology 147, 335–338. (doi:10.1007/s002130051177)
78. Zangara A, Blair RJ, Curran HV. 2002 A comparison of the effects of a beta-adrenergic blocker and a benzodiazepine upon the recognition of human facial expressions. Psychopharmacology 163, 36–41. (doi:10.1007/s00213-002-1120-4)
79. Murphy SE, Downham C, Cowen PJ, Harmer CJ. 2008 Direct effects of diazepam on emotional processing in healthy volunteers. Psychopharmacology 199, 503–513. (doi:10.1007/s00213-008-1082-2)
80. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. 2007 Efficacy and safety of the weightloss drug rimonabant: a meta-analysis of randomised trials. Lancet 370, 1706–1713. (doi:10.1016/s0140-6736(07)61721-8)
81. Horder J, Cowen PJ, Di Simplicio M, Browning M, Harmer CJ. 2009 Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers Psychopharmacology 205, 85–91. (doi:10.1007/s00213-009-1517-4)
82. Horder J, Browning M, Di Simplicio M, Cowen PJ, Harmer CJ. 2012 Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing J. Psychopharmacol. 26, 125–132. (doi:10.1177/0269881111400649)
83. Zarate Jr CA, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS. 2006 A double-blind, placebo-controlled study of memantine in the treatment of major depression Am. J. Psychiatry 163, 153–155. (doi:10.1176/appiajp.163.1.153)
84. Pringle A, Parsons E, Cowen LG, McTavish SF, Cowen PJ, Harmer CJ. 2012 Using an experimental medicine model to understand the antidepressant potential of the N-methyl-D-aspartic acid (NMDA) receptor antagonist memantine. J. Psychopharmacol 26, 1417–1423. (doi:10.1177/0269881112446535)
85. Keller M et al. 2006 Lack of efficacy of the substance P (Neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 59, 216–223. (doi:10.1016/j.biopsych2005.07.013)
86. Kramer MS et al. 2004 Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression Neuropsychopharmacology 29, 385–392. (doi:10.1038/sj.npp.1300260)
87. McCabe C, Cowen PJ, Harmer CJ. 2009 NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers. Int. J Neuropsychopharmacol. 12, 1261–1274. (doi:10.1017/s1461145709990150)
88. Chandra P, Hafizi S, Massey-Chase RM, Goodwin GM, Cowen PJ, Harmer CJ. 2010 NK1 receptor antagonism and emotional processing in healthy volunteers. J. Psychopharmacol. 24, 481–487 (doi:10.1177/0269881109103101)
89. Pringle A, McTavish SF, Williams C, Smith R, Cowen PJ, Harmer CJ. 2011 Short-term NK1 receptor antagonism and emotional processing in healthy volunteers. Psychopharmacology 215, 239–246 (doi:10.1007/s00213-010-2133-z)
90. Harmer CJ et al. 2013 Combined NK1 antagonism and serotonin reuptake inhibition: effects on emotional processing in humans J. Psychopharmacol. 27, 435–443. (doi:10.1177/0269881112472558)
91. Godlewska BR, Browning M, Norbury R, Cowen PJ, Harmer CJ. 2014 Early changes in neural response to emotional stimuli predict clinical response to SSRI treatment in depression. J. Psychopharmacol. (Suppl.) 28, A45
92. Trivedi MH et al. 2006 Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am. J. Psychiatry 163, 28–40. (doi:10.1176/appiajp.163.1.28)
93. Porcelli S, Fabbri C, Serretti A. 2012 Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy Eur. Neuropsychopharmacol. 22, 239–258. (doi:10.1016/j.euroneuro.2011.10.003)
94. Outhred T, Das P, Dobson-Stone C, Felmingham KL, Bryant RA, Nathan PJ, Malhi GS, Kemp AH. 2014 The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: preliminary findings from a randomised, crossover fMRI study. Aust. N. Z. J. Psychiatry 48, 1115–1125. (doi:10.1177/0004867414533837)
95. de Quervain DJF, Kolassa I-T, Ertl V, Onyut PL, Neuner F, Elbert T, Papassotiropoulos A. 2007 A deletion variant of the a2b-adrenoceptor is related to emotional memory in Europeans and Africans Nat. Neurosci. 10, 1137–1139. (doi:10.1038/nn1945)
96. Gibbs AA, Bautista CE, Mowlem FD, Naudts KH, Duka T. 2013 a2B adrenoceptor genotype moderates effect of reboxetine on negative emotional memory bias in healthy volunteers J. Neurosci. 33, 17023–17028. (doi:10.1523/jneurosci.2124-13.2013)
97. Rush AJ et al. 2006 Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report Am. J. Psychiatry 163, 1905–1917. (doi:10.1176/appi.ajp.163.11.1905)
98. Alural B, Duran GA, Tufekci KU, Allmer J, Onkal Z, Tunali D, Genc K, Genc S. 2014 EPO mediates neurotrophic, neuroprotective, anti-oxidant, and antiapoptotic effects via downregulation of mir-451 and miR-885–5p in SH-SY5Y neuron-like cells. Front Immunol. 5, 475. (doi:10.3389/fimmu.2014.00475)
99. Miskowiak K, O’Sullivan U, Harmer CJ. 2007 Erythropoietin reduces neural and cognitive processing of fear in human models of antidepressant drug action. Biol. Psychiatry 62, 1244–1250. (doi:10.1016/j.biopsych.2007.01.011)
100. Miskowiak K, Inkster B, Selvaraj S, Wise R, Goodwin GM, Harmer CJ. 2008 Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration Neuropsychopharmacology 33, 611–618. (doi:10.1038/sj.npp.1301439)
101. Miskowiak K, Favaron E, Hafizi S, Inkster B, Goodwin G, Cowen P, Harmer C. 2009 Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. Psychopharmacology 207, 133–142. (doi:10.1007/s00213-009-1641-1)
102. Miskowiak KW, Vinberg M, Christensen EM, Bukh JD, Harmer CJ, Ehrenreich H, Kessing LV. 2014 Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial Neuropsychopharmacology 39, 1399–1408. (doi:10.1038/npp.2013.335)
103. Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, Geddes JR, McShane R 2014 Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic J. Psychopharmacol. 28, 536–544. (doi:10.1177/0269881114527361)
104. Murrough JW et al. 2013 Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistr ant majodepression Biol. Psychiatry 74, 250–256. (doi:10.1016/jbiopsych.2012.06.022)
105. Abel KM, Allin MP, Kucharska-Pietura K, David A, Andrew C, Williams S, Brammer MJ, Phillips ML 2003 Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study Neuroreport 14, 387–391. doi:10.1097/01.wnr0000058031.29600.31
106. Deakin JFW, Williams S, Downey D, McKie S, Goodwin GM, Rylands A, Harmer CJ, Craig KJ, Dourish CT, Dawson GR, McCarthy CJ, Smith MA 2012 PharmacoMRI and cognitive effects of the low-trapping NMDA channel blocker AZD6765 compared with ketamine in untreated major depressive disorder. 28th CINP World Congress of Neuropsychopharmacology, Stockholm, Sweden, 3–7 June 2012
107. Stuart SA, Butler P, Nutt DJ, Robinson ESJ 2012 Investigating the mechanism underlying delayed versus rapid antidepressant action using a novel rodent model of affective stateinduced memory bias. J. Psychopharmacol 26, A46
108. Hajszan T, MacLusky NJ, Leranth C. 2005 Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. Eur. J. Neurosci 21, 1299–1303. (doi:10.1111/j.1460-9568.200503968.x)
109. Musazzi L, Cattaneo A, Tardito D, Barbon A, Gennarelli M, Barlati S, Racagni G, Popoli M. 2009 Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants. BMC Neurosci. 10, 48. (doi:10.1186/1471-2202-10-48)